Top Hematologic Malignancy News of 2016

Slideshow

This slide show highlights some of the top news of 2016 on hematologic malignancies, including FDA approvals for myeloma, lymphoma, and leukemia, and studies on transplantation, risk of recurrence in AML patients, and more.

Related Videos
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Related Content
The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024
Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Real-world data may serve as a benchmark for future studies in elderly patients with acute myeloid leukemia.

Data Show Improved Posttransplant Outcomes in Elderly AML Population

April 10th 2024
Article

Real-world data may serve as a benchmark for future studies in elderly patients with acute myeloid leukemia.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Findings suggest investigating an individualized monitoring period for stable patients with hematologic cancers to decrease financial and geographic barriers to CAR T-cell therapy.

Geographic/Financial Barriers to CAR T Therapy Exist in Hematologic Cancers

March 20th 2024
Article

Findings suggest investigating an individualized monitoring period for stable patients with hematologic cancers to decrease financial and geographic barriers to CAR T-cell therapy.

In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.

Evaluating Secondary Primary Malignancy Risk After CAR T-cell Therapy

March 14th 2024
Article

In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.